Radical increase in effectiveness of breast cancer immunotherapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, ICREA Professor, CIBERONC Investigator, Director of the Hospital del Mar Medical Research Institute (IMIM). view more
Credit: VHIO Redirection of lymphocytes, via T-cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs), is already approved to treat some hematologic malignancies. In solid tumors these immune-based strategies continue to fail. Research led by Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, has now shown how HER2 breast cancer cells adopt a strategy to resist clearance by redirected lymphocytes. Findings evidence that the disruption of interferon-gamma signaling confers resistance to these immunotherapies and promotes disease progression.